Method for detecting contents of antibodies and acid-base charge variants thereof in sample
The antibody and acid-base charge heterogeneous bodies in coprescription preparations were isolated and quantitatively analyzed by cation exchange chromatography (CEX-HPLC), which solved the problem that was difficult to determine in the prior art and achieved high precision and high repeatability. Quantitative analysis simplifies operations and reduces costs.
Patent Information
- Application Number
- CN202411303933.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to accurately determine the content of each antibody and its acid-base charged heterogeneous in coprescription formulations, especially when the antibodies are similar in physical and chemical properties and close in PI values, resulting in challenges in quality control and safety assessment.
The antibody and acid-base charge heterogeneous bodies in copreparation preparations were separated and quantitatively analyzed by gradient elution process by cation exchange chromatography (CEX-HPLC), and the difference in running time of different antibodies on the column were used to achieve separation and quantitative determination. .
High precision and high repeatability quantitative analysis of each antibody and its acid-base charged heterogeneous in coprescription preparations is achieved, which simplifies operation, reduces costs, and improves the throughput application of detection.
Smart Images

Figure CN119086770A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of bioanalysis. Specifically, the present application relates to a method for detecting the content of each antibody and its acid-base charge heterogeneous form in a sample. Background Art
[0002] Monoclonal antibody drugs have the unique advantages of strong specificity, high sensitivity and good safety, and have now become one of the mainstream developments in the global pharmaceutical field. In the process of antibody drug treatment, patients are often given multiple monoclonal antibodies for synergistic treatment at the same time. The efficacy of combined use of multiple monoclonal antibodies (mAb) is significantly better; and co-prescription protein preparations are combined into a single prescription through a combination medication mechanism and dosage, which brings more effectiveness and convenience to patients; for co-prescription preparations, regulatory agencies need a method to quantitatively confirm the composition and content of each component of co-prescription preparations; developers need a method to quantify the composition and content of each component of co-prescription preparations, while ensuring the stability of the process.
[0003] Combination therapy with multiple therapeutic antibodies can improve efficacy without sacrificing safety. Strategies for developing combination therapy include co-administration of two or more monoclonal antibodies (mAbs) and co-formulation of two or more monoclonal antibodies (mAbs) or bispecific antibodies (BsAbs) into one formulation (DP). In order to enable combination therapy using co-formulated antibody formulations, the safety and efficacy of the co-formulated formulation should be similar to that when multiple single-group formulations are co-administered; although the co-formulation approach offers several advantages, including reducing medication errors and enhancing patient convenience, it also increases the complexity of the drug and the difficulty of the product development process, posing quality challenges for product characterization and control. Even if the individual antibodies in the co-formulated formulation have completed comprehensive efficacy and safety testing as monotherapy drugs, it is important to conduct stability studies to demonstrate that the risk of interaction between them when used in combination is low. When multiple drugs are combined into a single formulation according to therapeutic needs, that is, co-formulation, the quality controllability and safety of each drug must be guaranteed. This challenge is particularly exacerbated when the antibodies in the co-formulated formulation have similar physicochemical properties and different concentrations. In addition, each antibody in a co-formulated formulation can exhibit manufacturing process heterogeneity in size, charge, and post-translational modifications. For these reasons, the interactions between the individual mAbs or bsAbs in the co-formulated formulation components need to be characterized and understood.
[0004] Existing literature reports on the content determination of co-prescription protein preparations, using HIC technology to separate and quantify the proteins in the co-prescription preparations. This method only determines the content of protein components in the sample, but cannot obtain more sample information. Another existing literature reports that SEC-HPLC (size exclusion chromatography) technology can determine the total aggregates when the components are similar, but cannot measure the specific content of each component. In addition, there are also literature reports that iCIEF (full-column imaging capillary isoelectric focusing electrophoresis technology) is the gold method for protein acid-base charge heterogeneities. However, it can only measure each protein in the co-prescription separately when the PI value difference is large. When the PI value difference of the protein in the co-prescription is small, the acid-base charge heterogeneities of protein 1 and the acid-base charge heterogeneities of protein 2 will overlap, interfering with the judgment.
[0005] In summary, developing a method that can determine the content of each protein and the acid-base charge heterogeneity of each component in co-prescription preparations containing two or more co-prescription preparations with similar physicochemical properties has become a technical problem that needs to be solved urgently in the development of co-prescription preparations. At the same time, due to the complexity of the simultaneous existence of multiple components, the development of this technology faces major challenges. Summary of the invention
[0006] In view of the problems existing in the prior art, the present application provides a method for detecting the content of each antibody and its acid-base charged heterogeneity in a sample, the method comprising: detecting the content of each antibody and its acid-base charged heterogeneity in the sample by cation exchange chromatography, wherein the sample contains at least two antibodies and their acid-base charged heterogeneity.
[0007] Beneficial effects:
[0008] The present application provides a method for quantifying the content of each antibody and the content of the corresponding acid-base charge heterogeneous substance from a sample containing two or more antibody molecules, the method comprising separating two or more antibodies and the acid-base charge heterogeneous substance of each antibody from a co-prescribed antibody preparation by cation exchange chromatography (CEX-HPLC), and quantifying the content of each antibody and the corresponding acid-base charge heterogeneous substance; wherein, when two or more antibodies are run separately on CEX-HPLC, they are eluted at different running times, respectively, and there is no overlap with other antibodies and the corresponding acid-base charge heterogeneous substance in the co-prescribed antibody preparation. At the same time, the above method has high precision and repeatability, and is simple to operate, low cost, can be applied in a high-throughput manner, and is easy to be widely promoted. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 The cation exchange chromatogram overlay of the co-prescription preparation in Example 1 of the present application is shown;
[0010] Figure 2The cation exchange chromatogram overlay of the co-prescription preparation in Example 2 of the present application is shown;
[0011] Figure 3 The cation exchange chromatogram overlay of the co-prescription preparation in Example 3 of the present application is shown;
[0012] Figure 4 The chromatogram overlay of the repeatability of 5 consecutive injections of the prescription preparation in Example 3 of the present application is shown;
[0013] Figure 5 The statistical chart of the applicability results of the continuous 5-injection system of the prescription preparation in Example 3 of the present application is shown;
[0014] Figure 6 The linear fitting diagram of the single prescription preparation mAb 1 in Example 3 of the present application is shown;
[0015] Figure 7 The linear fitting diagram of the single prescription formulation mAb 2 in Example 3 of the present application is shown;
[0016] Figure 8 The linear fitting diagram of the single prescription preparation mAb 3 in Example 3 of the present application is shown;
[0017] Fig. 9 The linear fitting diagram of the co-prescription preparation mAb 1 in Example 3 of the present application is shown;
[0018] Fig.10 The linear fitting diagram of the co-prescription preparation mAb 2 in Example 3 of the present application is shown;
[0019] Fig.11 The linear fitting diagram of the co-prescription preparation mAb 3 in Example 3 of the present application is shown;
[0020] Fig.12 , 13 14 and 15 show the superposition of cation exchange chromatograms obtained by detecting the co-prescription preparation in Example 4 of the present application under different mobile phase systems;
[0021] Fig.15 , 16 , 17 and 18 show the superposition of cation exchange chromatograms obtained by detecting the co-prescription preparation in Example 5 of the present application under different mobile phase systems;
[0022] Fig.19 An overlay of cation exchange chromatograms of the co-prescription preparation in Example 6 of the present application is shown;
[0023] Fig. 20 and 21 The cation exchange chromatograms obtained by detecting the co-prescription preparation in Example 7 of the present application under different mobile phase systems are shown;
[0024] Fig. 22 and 23 The cation exchange chromatograms obtained by detecting the co-prescription preparation in Example 8 of the present application under different mobile phase systems are shown;
[0025] Fig.24 The cation exchange chromatogram overlay of the co-prescription preparation in Comparative Example 1 of the present application is shown;
[0026] Fig.25 The cation exchange chromatogram overlay of the co-prescription preparation in Comparative Example 2 of the present application is shown. DETAILED DESCRIPTION
[0027] In the description of the present application, unless otherwise specified, “above” and “below” include the number.
[0028] Unless otherwise specified, the terms used in this application have the commonly known meanings generally understood by those skilled in the art. Unless otherwise specified, the numerical values of the various parameters mentioned in this application can be measured using various measurement methods commonly used in the art (for example, they can be tested according to the methods given in the examples of this application).
[0029] A list of items connected by the terms "at least one of," "at least one of," "at least one of," or other similar terms may mean any combination of the listed items. For example, if items A and B are listed, the phrase "at least one of A and B" means only A; only B; or A and B. In another example, if items A, B, and C are listed, the phrase "at least one of A, B, and C" means only A; or only B; only C; A and B (excluding C); A and C (excluding B); B and C (excluding A); or all of A, B, and C. Item A may contain a single component or multiple components. Item B may contain a single component or multiple components. Item C may contain a single component or multiple components.
[0030] The present application provides a method for detecting the content of each antibody and its acid-base charge heterogeneity in a sample, the method comprising: detecting the content of each antibody and its acid-base charge heterogeneity in the sample by cation exchange chromatography, wherein the sample contains at least two antibodies and their acid-base charge heterogeneity.
[0031] The present application provides a method for quantifying the content of each antibody and the content of the corresponding acid-base charge heterogeneous body from a sample containing two or more antibody molecules, the method comprising separating two or more antibodies and the acid-base charge heterogeneous bodies of each antibody from a co-prescribed antibody preparation by cation exchange chromatography (CEX-HPLC), and quantifying the content of each antibody and the corresponding acid-base charge heterogeneous body; wherein, when two or more antibodies are run separately on CEX-HPLC, they are eluted at different running times, respectively, and there is no overlap with other antibodies and the corresponding acid-base charge heterogeneous bodies in the co-prescribed antibody preparation. The above method can determine the concentration of each antibody content and its acid-base charge heterogeneous body in two or more antibody co-prescription preparations with similar physicochemical properties and close PI values. At the same time, the above method has high precision and repeatability, and is simple to operate, low cost, can be applied in a high-throughput manner, and is easy to be widely promoted.
[0032] If two or more antibodies in a co-formulation are run on CEX-HPLC, the elution curves of the antibodies monitored by the chromatograph by absorbance and elution time have significant overlap, which indicates that the two antibodies or their acid-base charge heterogeneities are eluted at close times, indicating that the two or more antibodies in the co-formulation antibody preparation lack separation in the chromatographic column, thereby obtaining antibody peaks with poor specificity. In this case, due to the significant overlap, it is impossible to quantify a single antibody or its acid-base charge heterogeneity. In some embodiments, when running on CEX-HPLC, the elution curves of the antibodies monitored by absorbance and elution time in the chromatograph of two or more antibodies from the co-formulation antibody preparation have almost no overlap, indicating that the antibodies are eluted at different time points and separated.
[0033] Cation exchange chromatography (CEX-HPLC) is based on the mutual adsorption between the positive charge on the antibody surface and the anion on the chromatographic column filler, which allows the charged antibody to be retained in the column. Due to the differences in surface charge and charge distribution of different antibodies, different retention times are obtained in the column, thereby separating the components and achieving the purpose of quantitatively detecting each antibody and its acid-base charge heterogeneities.
[0034] In some embodiments of the present application, the above-mentioned detection process is a gradient elution process, and the first mobile phase and the second mobile phase are used in the gradient elution process. The first mobile phase includes a first buffer solution and hydrochloric acid. The first buffer solution is a mixture of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane. The second mobile phase includes the first buffer solution.
[0035] The above method can determine the content of each antibody and the concentration of its acid-base charge heterogeneity in two or more co-prescription preparations of antibodies with similar physicochemical properties and close PI values. The pH elution gradient is completed under the gradient elution procedure using cation exchange chromatography and a buffer salt, thereby increasing the retention and separation of each protein, achieving the separation and quantification of each antibody and its acid-base charge heterogeneity in the co-prescription preparation, and assisting the study of the content of each antibody and its acid-base charge heterogeneity in the process research of the co-prescription preparation. At the same time, during the detection process, the present application uses a specific type of mobile phase for gradient elution to make the content detection results of each antibody and its acid-base charge heterogeneity obtained by the detection more accurate.
[0036] Any suitable CEX-HPLC column can be used in the method provided above in this application, including but not limited to Thermo ProPac WCX-10, Thermo ProPac SCX-10, Agilent Bio WCX, NP5, Agilent BioSCX, NP5.
[0037] Depending on the type and ratio of the antibodies, the composition of the first buffer can be optimized and adjusted. In some embodiments of the present application, in the first buffer, the ratio of the amount of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane is (1-6):(1-6):(1-6). The ratio of the amount of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane includes but is not limited to the above range, and limiting it within the above range is conducive to increasing the time interval between the peaks of each antibody and its acid-base charge heterogeneity, thereby better achieving the separation of the target component and further improving the accuracy of the test results.
[0038] In some embodiments of the present application, the pH of the first mobile phase is 5.0 to 6.5, and the pH of the second mobile phase is 9.0 to 11.5. Preferably, the pH of the second mobile phase depends on the pH after the components forming the mobile phase are mixed, and no additional pH adjustment process is performed. Compared with other ranges, limiting the pH of the first mobile phase and the second mobile phase to the above range is conducive to making the peak shape of the target component sharper and more symmetrical, while reducing the risk of tailing, thereby further improving the accuracy of the detection data of each component. Exemplarily, the pH of the first mobile phase is 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, or a range between any two of the above values.
[0039] For some components that are difficult to elute, adding inorganic salts to the mobile phase can suppress the charge intensity of the protein surface, reduce the interaction between the target component and the stationary phase, and thus reduce the residence time of the target component in the chromatographic column. In some embodiments of the present application, the first mobile phase includes water and / or sodium chloride in addition to the first buffer. Optionally, the pH of the first mobile phase is 5.0 to 6.5, and the pH of the second mobile phase is 9.0 to 11.5. Exemplarily, the pH of the first mobile phase is 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, or a range between any two of the above values. Preferably, the pH of the second mobile phase depends on the pH after the components forming the mobile phase are mixed, and no additional pH adjustment process is performed. The amount of sodium chloride is added according to actual needs, and preferably, the amount of sodium chloride added is 10mmol / L to 100mmol / L. In some embodiments of the present application, in the first buffer, the concentrations of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane are 2mmol / L to 12mmol / L, 2mmol / L to 12mmol / L, and 2mmol / L to 12mmol / L, respectively. The concentrations of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane include but are not limited to the above ranges, and limiting them within the above ranges is conducive to further improving the separation degree of each antibody and making the detection data accurate. Exemplarily, in the first buffer, the concentration of imidazole may be 2mmol / L, 3mmol / L, 4mmol / L, 5mmol / L, 6mmol / L, 7mmol / L, 8mmol / L, 9mmol / L, 10mmol / L, 11mmol / L, 12mmol / L, or a range formed by any of the above values; the concentration of 2-methylpiperazine may be 2mmol / L, 3mmol / L, 4mmol / L, 5mmol / L, 6mmol / L, 7mmol / L, 8mmol / L, 9mmol / L, 10mmol / L, 11mmol / L, 12mmol / L, or a range formed by any of the above values; the concentration of trishydroxymethylaminomethane may be 2mmol / L, 3mmol / L, 4mmol / L, 5mmol / L, 6mmol / L, 7mmol / L, 8mmol / L, 9mmol / L, 10mmol / L, 11mmol / L, 12mmol / L, or a range formed by any of the above values.
[0040] In order to further improve the accuracy of the test results, preferably, the detection process is carried out in a high performance liquid chromatograph equipped with an ion exchange chromatography column, and the detection conditions are as follows: the column temperature is 10°C to 50°C, the flow rate is 0.2mL / min to 1.5mL / min, the injection volume is 5μL to 100μL, and the detector is an ultraviolet detector, a diode array detector or a fluorescence detector.
[0041] If there is a big difference in PI values between antibodies calculated or estimated by protein structure, sequence-based structural models, protein sequences and other known aspects of protein structure, CIEF method can be used for determination. Of course, CEX-HPLC is still a simple and effective method. However, when the PI difference is small, the detection result of CEX-HPLC is more accurate. In some embodiments of the present application, the PI difference of each antibody is below 0.90. In some embodiments of the present application, the PI difference of each antibody is 0.03 to 0.90, such as 0.03, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90 or the range formed by any of the above values.
[0042] In order to reduce the influence of solid impurities or undissolved components on the chromatographic peak, the first mobile phase and the second mobile phase are filtered before the determination, and / or the target sample (or the target sample dissolved in a solvent such as pure water or a mobile phase) is filtered. The filtration accuracy can be optimized according to the actual situation, such as a filtration pore size of 0.22 μm.
[0043] Some embodiments of the present application provide a method for quantifying antibody 1 and antibody 2 in a co-prescription preparation of two proteins, the method comprising: using cation exchange high performance liquid chromatography (CEX-HPLC) to separate antibody 1 and its acid-base charge heterogeneities from antibody 2 and its acid-base charge heterogeneities, and quantifying the content of antibody 1 and its acid-base charge heterogeneities, and the content of antibody 2 and its acid-base charge heterogeneities, wherein when antibody 1 and antibody 2 are run separately on CEX-HPLC, the elution time of the main peak of antibody 1 and its acid-base charge heterogeneities and the main peak of antibody 2 and its acid-base charge heterogeneities are both specific.
[0044] Some embodiments of the present application provide a method for quantifying antibody 1, antibody 2, antibody 3, antibody 4 or antibody 5 in a co-prescription preparation of three or more proteins, the method comprising: using cation exchange high performance liquid chromatography (CEX-HPLC) to separate antibody 1, antibody 2, antibody 3, antibody 4 or antibody 5 and their acid-base charge heterogeneities, and quantifying the content of antibody 1, antibody 2, antibody 3, antibody 4 or antibody 5 and their acid-base charge heterogeneities, wherein when antibody 1, antibody 2, antibody 3, antibody 4 or antibody 5 are run separately on CEX-HPLC, the elution time of the main peak of antibody 1 and its acid-base charge heterogeneities does not overlap with the elution time of the main peak of other antibodies (antibody 2, antibody 3, antibody 4 or antibody 5) and their acid-base charge heterogeneities, and both are specific.
[0045] Preferably, the above quantitative process adopts the external standard method.
[0046] In some embodiments of the present application, the content of each antibody in an unknown sample is quantified by establishing a standard curve by comparing the absorbance of the antibody at 280 nm with the corresponding concentration. The standard curve can be constructed by determining the absorbance of known antibodies at known concentrations from the CEX-HPLC run, for example, at 280 nm, the higher the protein concentration, the higher the absorbance, and the absorbance data of antibodies of known concentrations are used to make a standard curve, plotting the concentration on the X-axis and the absorbance of the corresponding antibody on the Y-axis; the absorbance value of each antibody in the co-prescription sample (determined by its retention time) is used to locate the corresponding concentration value on the standard curve.
[0047] For example, CEX-HPLC can be used to qualitatively characterize different antibody molecules and acid-base charge heterogeneities of each antibody in co-prescribed protein preparations. Each antibody is run separately on CEX-HPLC, and the running time of the corresponding antibody is determined. The peak with the highest percentage content is the main peak of the corresponding antibody, the front eluting peak of the antibody is the acidic peak of the antibody, and the back eluting peak of the antibody is the alkaline peak of the antibody. The elution time of each antibody and the corresponding acid peak and alkaline peak are confirmed in turn.
[0048] For the above-mentioned detection object samples, as long as they contain two or more antibodies and their acid-base charge heterogeneities, and the elution curves of each antibody do not overlap, the above-mentioned method can be used for determination, and the specific types and compositions need not be elaborated.
[0049] In some embodiments of the present application, the above-mentioned sample includes at least two antibodies and their acid-base charge heterogeneities, and the above-mentioned sample is a raw material drug containing at least two antibodies and their acid-base charge heterogeneities, or the above-mentioned sample is a preparation containing at least two antibodies and their acid-base charge heterogeneities, or it includes both the raw material and the preparation, and each of the raw material and the preparation contains at least one antibody and its acid-base charge heterogeneity.
[0050] In some embodiments of the present application, each of the above antibodies is a monoclonal antibody (such as immunoglobulin IgG1, IgG4), or at least one antibody is a bispecific antibody (such as BsAb).
[0051] In some embodiments of the present application, the sample is a single co-prescribed protein preparation, or a mixture of at least two single co-prescribed protein preparations.
[0052] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. In the absence of conflict, the following embodiments and features in the embodiments can be combined with each other.
[0053] Example 1
[0054] 1. Sample information
[0055] The co-formulated formulation used in Example 1 contains two monoclonal antibodies (mAb 1 and mAb 2, IgG1 and IgG4, respectively) with similar molecular weight (e.g., mAb 1 is 145.5 kDa and mAb 2 is 146.4 kDa), protein structure and charge characteristics (e.g., the PI of mAb 1 is 8.5 and the PI of mAb 2 is 7.6, with a maximum PI difference of 0.9).
[0056] The CEX-HPLC method was used to quantify two monoclonal antibodies (mAb 1 and mAb 2) with similar molecular weight, protein structure and charge properties in a co-formulated formulation. The two monoclonal antibodies and their corresponding acid-base charge variants were first separated from the co-formulated formulation, and then each monoclonal antibody and its acid-base charge variants were quantified.
[0057] Table 1 Prescription information of the preparation samples in Example 1
[0058]
[0059] 2. Instrument and reagent information
[0060] Agilent 1260 liquid chromatography system, CDS data processing software; Milli-Q ultrapure water system;
[0061] Imidazole: reagent grade, from Sigma, batch number SLCN3998;
[0062] 2-Methylpiperazine: reagent grade, from Jiuding Chemical, batch number SBJNWKK;
[0063] Tris(hydroxymethyl)aminomethane: from Roche, batch number 10098827;
[0064] HCl (37%): from Merck, batch number K51237314910.
[0065] 3. Chromatographic conditions:
[0066] The CEX-HPLC methods are shown below. In each method, 100 μg (50 μg each for mAb 1 and mAb 2) of sample was loaded and detected with UV detector at 280 nm using gradient elution mode.
[0067] Preparation of mobile phase:
[0068] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole, and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole, and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely, and then make up to 1000mL);
[0069] Mobile phase A (first mobile phase): a solution containing 4mmol / L 2-methylpiperazine, 4mmol / L imidazole and 4mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 100mL of the stock solution, add about 800mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0070] Mobile phase B (second mobile phase): a solution containing 4 mmol / L 2-methylpiperazine, 4 mmol / L imidazole and 4 mmol / L tris(hydroxymethylaminomethane) (accurately measure 100 mL of the stock solution, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane); the chromatographic column is ThermoProPacWCX-10, 4×250 mm, 10 μm (PN.: 054993).
[0071] Table 2 CEX-HPLC method parameter settings for two antibody co-prescription preparations
[0072]
[0073]
[0074] Example 1 Overlay of co-prescription preparations ( Figure 1) shows that the main peaks of mAb 1 and mAb 2 have been completely separated, and their respective acid-base charge heterogeneities have also been effectively separated. It should be noted that, for the peak positions of acid-base charge heterogeneities, the chromatographic peak before the main peak of mAb1 is the acidic charge heterogeneity chromatographic peak of mAb 1, and the chromatographic peak after the main peak of mAb 1 is the basic charge heterogeneity chromatographic peak of mAb 1; the chromatographic peak before the main peak of mAb 2 is the acidic charge heterogeneity chromatographic peak of mAb 2, and the chromatographic peak after the main peak of mAb 2 is the basic charge heterogeneity chromatographic peak of mAb 2. The peak positions of acid-base charge heterogeneities in other embodiments are the same as this determination method.
[0075] Example 2
[0076] 1. Sample information
[0077] The co-formulated formulation used in Example 2 contains two monoclonal antibodies (mAb 1 and mAb 2 are both IgG1) and a bispecific antibody (BsAb) with similar molecular weight (e.g., mAb 1 is 145.5 kDa, mAb 2 is 141.8 kDa and BsAb is 153.3 kDa), protein structure and charge characteristics (e.g., the PI of mAb 1 is 8.39, the PI of mAb 2 is 8.25 and the PI of BsAb is 7.77; the maximum difference in PI is 0.62).
[0078] The CEX-HPLC method was used to quantify two monoclonal antibodies (mAb 1 and mAb 2) and a bispecific antibody (BsAb) with similar molecular weight, protein structure and charge properties in a co-formulated formulation. The three antibodies and their corresponding acid-base charge variants were first separated from the co-formulated formulation, and then each monoclonal antibody and its acid-base charge variants were quantified.
[0079] Table 3 Prescription information of the preparation samples in Example 2
[0080]
[0081] 2. Instrument and reagent information
[0082] Agilent 1260 liquid chromatography system, CDS data processing software; Milli-Q ultrapure water system;
[0083] Imidazole: reagent grade, from Sigma, batch number SLCN3998;
[0084] 2-Methylpiperazine: reagent grade, from Jiuding Chemical, batch number SBJNWKK;
[0085] Tris(hydroxymethyl)aminomethane: from Roche, batch number 10098827;
[0086] HCl (37%): from Merck, batch number K51237314910.
[0087] 3. Chromatographic conditions:
[0088] The CEX-HPLC method is shown below, with 48 μg (20 μg each of mAb 1, mAb 2 and BsAb 3) sample loaded, detected at 280 nm with UV detector, using gradient elution mode.
[0089] Preparation of mobile phase:
[0090] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0091] Mobile phase A (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0092] Mobile phase B (second mobile phase): a solution containing 8 mmol / L 2-methylpiperazine, 8 mmol / L imidazole and 8 mmol / L tris(hydroxymethyl)aminomethane, pH 10.8 (accurately measure 200 mL of the stock solution, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane); the chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250 mm (PN.:5190-2427).
[0093] Table 4 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0094]
[0095]
[0096] Example 2 Overlay of co-prescription preparations ( Figure 2 ) showed that the main peaks of mAb 1, mAb 2 and BsAb were completely separated, and their respective acid-base charged isomers were also effectively separated.
[0097] Example 3
[0098] 1. Sample information
[0099] The co-formulated formulation used in Example 3 contains three monoclonal antibodies (mAb 1, mAb 2 and mAb 3 are IgG1, IgG1 and IgG4, respectively) with similar molecular weights (e.g., mAb 1 is 145.5 kDa, mAb 2 is 141.8 kDa and mAb 3 is 145.0 kDa), protein structures and charge properties (e.g., the PI of mAb 1 is 8.39, the PI of mAb 2 is 8.25 and the PI of mAb 3 is 8.36, with the maximum PI difference being only 0.14).
[0100] The CEX-HPLC method was used to quantify three monoclonal antibodies (mAb 1, mAb 2, and mAb 3) with similar molecular weight, protein structure, and charge properties in a co-formulated formulation by first separating the three mAbs and the corresponding acid-base charge variants from the co-formulated formulation and then quantifying each mAb and the corresponding acid-base charge variants.
[0101] Table 5 Prescription information of the preparation samples in Example 3
[0102]
[0103] 2. Instrument and reagent information
[0104] Agilent 1260 liquid chromatography system, CDS data processing software; Milli-Q ultrapure water system;
[0105] Imidazole: reagent grade, from Sigma, batch number SLCN3998;
[0106] 2-Methylpiperazine: reagent grade, from Jiuding Chemical, batch number SBJNWKK;
[0107] Tris(hydroxymethyl)aminomethane: from Roche, batch number 10098827;
[0108] HCl (37%): from Merck, batch number K51237314910.
[0109] 3. Chromatographic conditions:
[0110] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0111] Preparation of mobile phase:
[0112] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0113] Mobile phase A (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0114] Mobile phase B (second mobile phase): a solution containing 8 mmol / L 2-methylpiperazine, 8 mmol / L imidazole and 8 mmol / L tris(hydroxymethyl)aminomethane, pH 10.8 (accurately measure 200 mL of the stock solution, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane); the chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250 mm (PN.:5190-2427).
[0115] Table 6 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0116]
[0117]
[0118] Example 3 Overlay of co-prescription preparations ( Figure 3 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 and their corresponding acid-base charged isomers were effectively separated.
[0119] 4. Exclusivity:
[0120] The specificity of the CEX-HPLC method was confirmed using single standards and sample blanks.
[0121] To confirm the complete separation of the three mAbs and their corresponding acid-base isomers, sample blanks, co-formulated preparations, and standard mAb solutions were run separately, and the assay chromatograms were overlapped to confirm complete separation.
[0122] 5. System suitability:
[0123] In order to confirm the system stability of the co-prescription preparation samples, the samples were injected 5 times repeatedly, and the RSD% of the main peak, acid peak and base peak percentages and the ratio of two antibodies met the acceptance criteria.
[0124] Table 7 Repeatability results of three antibody co-formulations
[0125]
[0126]
[0127] Figure 4 The chromatograms are stacked for the reproducibility of 5 consecutive injections of the co-prescription preparation of the three antibodies in Example 3. Figure 4 It can be seen that the repeatability test data of 5 consecutive needles remain consistent, which indicates that the sample has good repeatability under this method.
[0128] It should be noted that in this application, "antibody Acid" refers to the acidic charge variant of the antibody, and "antibody Base" refers to the basic charge variant of the antibody. For example, mAb 1Acid refers to the acidic charge variant of the antibody mAb 1, and mAb 1Base refers to the basic charge variant of the antibody mAb 1. In this application, "Co mAb" refers to a co-prescription preparation.
[0129] Figure 5 This is a statistical chart of the system suitability results for 5 consecutive injections of the co-prescription preparation in Example 3. Figure 5 It shows that the test results of each component remain stable under repeated injection.
[0130] 6. Linear:
[0131] To calculate the content of each antibody in the co-prescription formulation, run the known concentrations of the single-prescription monoclonal antibody standard solutions and the co-prescription formulations to prepare a standard single-prescription monoclonal antibody standard solution containing 2 mg / mL of each antibody and a 6 mg / mL co-prescription solution (for example: containing 2 mg / mL of mAb 1, 2 mg / mL of mAb 2 and 2 mg / mL of mAb 3) and test according to Table 8.
[0132] Table 8 Linear run list of single prescription antibodies and co-prescription antibodies
[0133]
[0134]
[0135] The contents of mAb 1, mAb 2, and mAb 3 and their corresponding acid-base charged variants in the co-formulated preparations were calculated using linear equations of known concentrations of the single-formulated antibodies.
[0136] The calculation formula is as follows:
[0137]
[0138] Where: C mAbn : is the concentration of the corresponding mAbn in the co-prescription in mg / mL; A mAbn : is the peak area of the corresponding mAbn in the co-prescription; b mAbn : is the intercept of the linear equation corresponding to the mAbn in a single prescription; a mAbn : is the slope of the linear equation corresponding to mAb n in a single prescription; Note: mAbn content can be calculated by the sum of the main peak, acid peak and base peak, and n represents the antibody number.
[0139] Figure 6 , Figure 7 , Figure 8 The linear fitting graphs of the single-prescription mAb 1, the single-prescription mAb 2, and the single-prescription mAb 3 in Example 3 are shown in order.
[0140] Fig. 9 , Fig.10 , Fig.11 The linear fitting graphs of co-prescription mAb 1, co-prescription mAb 2 and co-prescription mAb 3 in Example 3 are shown in order.
[0141] 7. Precision:
[0142] In order to confirm the precision of the content of each monoclonal antibody in the co-prescription preparation, the co-prescription preparation samples and the co-prescription preparations measured by different analysts on different dates were run continuously. The specific test data are shown in Table 9. It was calculated that the precision of the co-prescription preparation samples met the acceptance criteria.
[0143] Table 9 Precision results
[0144]
[0145]
[0146] Example 4
[0147] Example 4 was carried out with reference to Example 3, except that the pH of the first mobile phase was 5.5, 6.0, and 6.5, and the pH of the second mobile phase was 10.8.
[0148] Chromatographic conditions:
[0149] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0150] Preparation of mobile phase:
[0151] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0152] Mobile phase A1 (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 5.5 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 5.5 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0153] Mobile phase A2 (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 6.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 6.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0154] Mobile phase A3 (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 6.5 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 6.5 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0155] Mobile phase B (second mobile phase): a solution containing 8 mmol / L 2-methylpiperazine, 8 mmol / L imidazole and 8 mmol / L tris(hydroxymethyl)aminomethane, pH 10.8 (accurately measure 200 mL of the stock solution, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane); the chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250 mm (PN.:5190-2427).
[0156] Table 10 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0157]
[0158] Example 4 Overlay of the above co-prescription preparations ( Fig.12 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 and their corresponding acid-base charged isomers were effectively separated.
[0159] Table 11 CEX-HPLC method parameter settings for triple antibody co-prescription preparation
[0160]
[0161]
[0162] Example 4 Overlay of the above co-prescription preparations ( Fig.13 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 and their corresponding acid-base charged isomers were effectively separated.
[0163] Table 12 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0164]
[0165]
[0166] Example 4 Overlay of the above co-prescription preparations ( Fig.14 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 and their corresponding acid-base charged isomers were effectively separated.
[0167] Example 5
[0168] Example 5 was carried out with reference to Example 3, except that the pH of the second mobile phase was 11.5, 10.0, 9.5 and 9.0.
[0169] Chromatographic conditions:
[0170] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0171] Preparation of mobile phase:
[0172] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0173] Mobile phase A (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0174] Mobile phase B1 (second mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 11.5 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 11.5 with 2mol / L NaOH, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0175] Mobile phase B2 (second mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 10.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 10.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0176] Mobile phase B3 (second mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 9.5 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 9.5 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0177] Mobile phase B4 (second mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 9.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 9.0 with 1mol / L HCl, then add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane); the chromatographic column is Agilent BioSCX, NP5, PK 4.6×250mm (PN.:5190-2427).
[0178] Table 13 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0179]
[0180]
[0181] Example 5 Overlay of the co-prescription preparation when the pH of mobile phase B (second mobile phase) is 11.5 ( Fig.15 ) showed that the main peaks of mAb1, mAb 2 and mAb 3 and the corresponding acid-base charged isomers were effectively separated.
[0182] Table 14 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0183]
[0184] Example 5 Overlay of co-prescription preparations when the pH of mobile phase B (second mobile phase) is 10.0 ( Fig.16 ) showed that the main peaks of mAb1, mAb 2 and mAb 3 and the corresponding acid-base charged isomers were effectively separated.
[0185] Table 15 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0186]
[0187] Example 5 Overlay of co-prescription preparations when the pH of mobile phase B (second mobile phase) is 9.5 ( Fig.17 ) shows that the main peaks of mAb1 and mAb 2 and the corresponding acid-base charge isomers are effectively separated. Since the pH of mobile phase B is reduced, the elution capacity of the system is reduced, so mAb 3 is strongly retained in this system and cannot be eluted within the method time range. In this case, a certain amount of inorganic salt can be added to the mobile phase.
[0188] Table 16 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0189]
[0190]
[0191] Example 5 Overlay of co-prescription preparations when the pH of mobile phase B (second mobile phase) is 9.0 ( Fig.18 ) showed that the main peaks of mAb1 and mAb 2 and the corresponding acid-base charge isomers were effectively separated. Due to the reduction of the pH of mobile phase B, the elution capacity of the system was reduced, resulting in mAb 3 being strongly retained in this system and unable to elute within the method time range.
[0192] Example 6
[0193] Example 6 was carried out with reference to Example 5, except that the pH of the second mobile phase was 9.0 and 50 mmol / L of sodium chloride was added.
[0194] Chromatographic conditions:
[0195] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0196] Preparation of mobile phase:
[0197] Stock solution: 40mmol / L 2-methylpiperazine, 40mmol / L imidazole, 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole, 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0198] Mobile phase A (first mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole and 8mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 200mL of the stock solution, add about 700mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0199] Mobile phase B (second mobile phase): a solution containing 8mmol / L 2-methylpiperazine, 8mmol / L imidazole, 8mmol / L tris(hydroxymethyl)aminomethane and 50mmol / L sodium chloride, pH 9.0 (accurately measure 200mL of the stock solution, add 700mL of ultrapure water and 2.9g of sodium chloride, adjust the pH to 9.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane); the chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250mm (PN.:5190-2427).
[0200] Table 17 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0201]
[0202]
[0203] Example 6 Overlay of Co-prescription Preparations ( Fig.19 ) showed that the main peaks of mAb 1, mAb 2 and mAb3 and the corresponding acid-base charged heterogeneities were effectively separated; when the sample exceeded the elution capacity of the method, adding an appropriate amount of inorganic salt could improve the elution capacity and achieve effective separation.
[0204] Example 7
[0205] Example 7 was carried out with reference to Example 3, with the only difference being that in the first mobile phase and the second mobile phase, the concentrations of 2-methylpiperazine, imidazole and tris(hydroxymethyl)aminomethane were 12 mmol / L, 2 mmol / L and 6 mmol / L respectively.
[0206] Chromatographic conditions:
[0207] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0208] Preparation of mobile phase:
[0209] Mobile phase A1 (first mobile phase): a solution containing 12 mmol / L 2-methylpiperazine, 2 mmol / L imidazole and 6 mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately weigh 1.2 g of 2-methylpiperazine, 0.135 g of imidazole and 0.73 g of tris(hydroxymethyl)aminomethane, respectively, and place them in a 1 L reagent bottle, add about 900 mL of ultrapure water, adjust the pH to 5.0 with 1 mol / L HCl, then add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane to obtain the result);
[0210] Mobile phase B1 (second mobile phase): a solution containing 12 mmol / L 2-methylpiperazine, 2 mmol / L imidazole and 6 mmol / L tris(hydroxymethylaminomethane) (accurately weigh 1.2 g of 2-methylpiperazine, 0.135 g of imidazole and 0.73 g of tris(hydroxymethylaminomethane) in a 1 L reagent bottle, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane).
[0211] Mobile phase A2 (first mobile phase): a solution containing 2mmol / L 2-methylpiperazine, 12mmol / L imidazole and 6mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately weigh 0.2g of 2-methylpiperazine, 0.81g of imidazole and 0.73g of tris(hydroxymethyl)aminomethane, respectively, and place them in a 1L reagent bottle, add about 900mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, then add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane to obtain the result);
[0212] Mobile phase B2 (second mobile phase): a solution containing 2 mmol / L 2-methylpiperazine, 12 mmol / L imidazole and 6 mmol / L tris(hydroxymethylaminomethane) (accurately weigh 0.2 g of 2-methylpiperazine, 0.81 g of imidazole and 0.73 g of tris(hydroxymethylaminomethane) in a 1 L reagent bottle, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane).
[0213] Table 18 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0214]
[0215] Example 7 Overlay of Co-prescription Preparations ( Fig. 20 ) showed that the main peaks of mAb 1 and mAb 2 and the corresponding acid-base charged isomers were effectively separated.
[0216] Table 19 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0217]
[0218]
[0219] Example 7 Overlay of Co-prescription Preparations ( Fig.21 ) showed that the main peaks of mAb 1 and mAb 2 and the corresponding acid-base charged isomers were effectively separated.
[0220] Example 8
[0221] Example 8 was carried out with reference to Example 3, with the only difference being that in the first mobile phase and the second mobile phase, the concentrations of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane were 2mmol / L, 2mmol / L, 2mmol / L and 12mmol / L, 12mmol / L, 12mmol / L, respectively.
[0222] Chromatographic conditions:
[0223] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0224] Preparation of mobile phase:
[0225] Stock solution: a solution containing 40mmol / L 2-methylpiperazine, 40mmol / L imidazole and 40mmol / L tris(hydroxymethylaminomethane) (accurately weigh 4.0g 2-methylpiperazine, 2.7g imidazole and 4.85g tris(hydroxymethylaminomethane) into a suitable container, add about 900mL ultrapure water, dissolve completely and then make up to 1000mL);
[0226] Mobile phase A1 (first mobile phase): a solution containing 2mmol / L 2-methylpiperazine, 2mmol / L imidazole and 2mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 50mL of the stock solution, add about 900mL of ultrapure water, adjust the pH to 5.0 with 1mol / L HCl, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane);
[0227] Mobile phase B1 (second mobile phase): a solution containing 2mmol / L 2-methylpiperazine, 2mmol / L imidazole and 2mmol / L tris(hydroxymethylaminomethane) (accurately measure 50mL of the stock solution, add ultrapure water to 1000mL, mix well, and filter with a 0.22μm filter membrane).
[0228] Mobile phase A2 (first mobile phase): a solution containing 12 mmol / L 2-methylpiperazine, 12 mmol / L imidazole and 12 mmol / L tris(hydroxymethyl)aminomethane, pH 5.0 (accurately measure 300 mL of the stock solution, add about 650 mL of ultrapure water, adjust the pH to 5.0 with 1 mol / L HCl, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane);
[0229] Mobile phase B2 (second mobile phase): a solution containing 12 mmol / L 2-methylpiperazine, 12 mmol / L imidazole and 12 mmol / L tris(hydroxymethylaminomethane) (accurately measure 300 mL of the stock solution, add ultrapure water to 1000 mL, mix well, and filter with a 0.22 μm filter membrane).
[0230] Table 20 CEX-HPLC method parameter settings for the three-antibody co-prescription preparation
[0231]
[0232]
[0233] Example 8 Overlay of the above co-prescription preparations ( Fig. 22 ) showed that the main peaks of mAb 1 and mAb 2 and the corresponding acid-base charged isomers were effectively separated.
[0234] Table 21 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0235]
[0236]
[0237] Example 8 Overlay of the above co-prescription preparations ( Fig.23) showed that the main peaks of mAb 1 and mAb 2 and the corresponding acid-base charged isomers were effectively separated.
[0238] Comparative Example 1
[0239] Comparative Example 1 was carried out with reference to Example 3, except that the mobile phase system was a conventional 2-morpholineethanesulfonic acid system.
[0240] 1. Instrument and reagent information
[0241] Agilent 1260 liquid chromatography system, CDS data processing software; Milli-Q ultrapure water system;
[0242] 2-Morpholineethanesulfonic acid: reagent grade, from Sigma, batch number BCCH3217;
[0243] Sodium chloride: reagent grade, from Sinopharm Reagent, batch number 20220829;
[0244] Sodium hydroxide: pharmaceutical excipient, sourced from Hunan Erkang Pharmaceutical Co., Ltd., batch number 100920221001.
[0245] 2. Chromatographic conditions:
[0246] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0247] 3. Preparation of mobile phase:
[0248] 2mmol / L sodium hydroxide: Accurately weigh about 4g of sodium hydroxide and place it in 50mL of ultrapure water until it dissolves completely.
[0249] Mobile phase A (first mobile phase): 30 mmol / L 2-morpholineethanesulfonic acid, pH 5.5 (accurately weigh 3.2 g of 2-morpholineethanesulfonic acid, place it in 500 mL of ultrapure water, dissolve and mix well, adjust the pH to 5.5 with 2 mol / L sodium hydroxide, and filter with a 0.22 μm filter membrane to obtain the product);
[0250] Mobile phase B (second mobile phase): a solution containing 30mmol / L 2-morpholineethanesulfonic acid and 50mmol / L sodium chloride, pH 5.5 (accurately weigh 3.2g of 2-morpholineethanesulfonic acid and 5.8g of sodium chloride, dissolve and mix in 500mL ultrapure water, adjust the pH to 5.5 with 2mmol / L sodium hydroxide, and filter with a 0.22μm filter membrane to obtain the result). The chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250mm (PN.:5190-2427).
[0251] Table 22 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0252]
[0253]
[0254] Comparative Example 1 Overlay of the co-prescription preparation ( Fig.24 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 were completely separated, while their corresponding acid-base charged heterogeneities were not effectively separated, and a large number of acid-base charged heterogeneities co-eluted.
[0255] Comparative Example 2
[0256] Comparative Example 2 was carried out with reference to Example 3, except that the mobile phase system was a conventional phosphoric acid system.
[0257] 1. Instrument and reagent information
[0258] Agilent 1260 liquid chromatography system, CDS data processing software; Milli-Q ultrapure water system;
[0259] Anhydrous sodium dihydrogen phosphate: reagent grade, from Sinopharm Reagent, batch number 20220826;
[0260] Sodium chloride: reagent grade, from Sinopharm Reagent, batch number 20220829;
[0261] Sodium hydroxide: pharmaceutical excipient, sourced from Hunan Erkang Pharmaceutical Co., Ltd., batch number 100920221001.
[0262] 2. Chromatographic conditions:
[0263] The CEX-HPLC method is shown below, loading 60 μg (20 μg each of mAb 1, mAb 2 and mAb 3) sample, monitoring at 280 nm with UV detector, using gradient elution mode.
[0264] 3. Preparation of mobile phase:
[0265] 2mmol / L sodium hydroxide: Accurately weigh about 4g of sodium hydroxide and place it in 50mL of ultrapure water until it dissolves completely.
[0266] Mobile phase A (first mobile phase): 30 mmol / L sodium dihydrogen phosphate solution, pH 5.5 (accurately weigh 1.8 g of anhydrous sodium dihydrogen phosphate, place it in 500 mL of ultrapure water, dissolve and mix, adjust the pH to 5.5 with 2 mmol / L sodium hydroxide, and filter with a 0.22 μm filter membrane to obtain);
[0267] Mobile phase B (second mobile phase): a solution containing 30mmol / L sodium dihydrogen phosphate and 50mmol / L sodium chloride, pH 5.5. (Accurately weigh 1.8g of anhydrous sodium dihydrogen phosphate and 5.8g of sodium chloride, place in 500mL ultrapure water, dissolve and mix, adjust pH to 5.5 with 2mmol / L sodium hydroxide, and filter with a 0.22μm filter membrane.) The chromatographic column is Agilent Bio SCX, NP5, PK 4.6×250mm (PN.:5190-2427).
[0268] Table 23 CEX-HPLC method parameter settings for triple antibody co-prescription preparations
[0269]
[0270]
[0271] Comparative Example 2 Overlay of the co-prescription preparation ( Fig.25 ) showed that the main peaks of mAb 1, mAb 2 and mAb 3 were completely separated, while their corresponding acid-base charged heterogeneities were not effectively separated, and a large number of acid-base charged heterogeneities co-eluted.
[0272] From the above description, we can see that:
[0273] It can be seen from Examples 1, 2 and 3 that when the difference in the pI values of the antibodies is small, the method provided in the present application can also completely separate the main peaks of the antibodies in the co-prescription preparation, and their corresponding acid-base charge heterogeneities can also be effectively separated.
[0274] By comparing Example 3 and Comparative Examples 1 to 2, it can be seen that when the difference in the pI values of the antibodies is small, the use of the preferred first mobile phase and second mobile phase of the present application is beneficial to effectively separate the corresponding acid-base charge heterogeneities while separating the antibodies in the sample.
[0275] By comparing Examples 3, 4 and 5, it can be seen that the pH range of the first mobile phase in the method provided in the present application can be adjusted within the range of 5.0-6.5 to meet the complete separation of the main peak and its charged heterogeneous phases, and further optimization of the pH is beneficial to improve its elution effect; the pH of the second mobile phase can be adjusted within the range of 10.0-11.5 to meet the complete separation of the main peak and its charged heterogeneous phases; according to the retention strength of the sample in the mobile phase, after adding inorganic salts to the buffer solution, the elution intensity can be increased, the selectivity can be changed, and more optimization space can be obtained.
[0276] Comparing Examples 5 and 6, it can be seen that the pH of the second mobile phase is in the range of 9.0-10.0. Since mAb3 is strongly retained and exceeds the elution range of the method, mAb3 cannot be eluted; (for samples with relatively weak retention, it can meet the analysis, such as: Co mAb samples composed of mAb1 and mAb2). Since mAb3 has exceeded the elution range of the method, adding inorganic salts (NaCl) to the mobile phase can increase the elution capacity of the mobile phase, so that the sample (sample solution of Example 3) can still meet the separation of the sample solution (main peak and isomer peak) when the pH of the second mobile phase is in the range of 9.0-10.0.
[0277] By comparing Examples 3, 7, and 8, it can be seen that the salt concentration of the mobile phase in the method provided in the present application can be optimized within the range of 2mmol / L-12mmol / L. Not only can the equimolar concentration of all salts be optimized, but also the mixed molar concentration of all salts can be optimized. At the same time, after adding inorganic salts, the elution strength of the buffer solution can be improved, thereby obtaining a wider optimization space.
[0278] Although some exemplary embodiments of the present application have been illustrated and described, the present application is not limited to the disclosed embodiments. On the contrary, those skilled in the art will recognize that some modifications and changes may be made to the described embodiments without departing from the spirit and scope of the present application as described in the appended claims.
Claims
1. A method for detecting the content of each antibody and its acid-base charged heterogeneous form in a sample, It is characterized in that The method comprises: The content of each antibody and its acid-base charged heterogeneity in the sample is detected by cation exchange chromatography, and the sample contains at least two antibodies and their acid-base charged heterogeneity.
2. The method according to claim 1, It is characterized in that The detection process is a gradient elution process, in which a first mobile phase and a second mobile phase are used, the first mobile phase includes a first buffer and hydrochloric acid, the first buffer is a mixture of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane, and the second mobile phase includes the first buffer.
3. The method according to claim 2, It is characterized in that In the first buffer solution, the molar ratio of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane is (1-6):(1-6):(1-6).
4. The method according to claim 2 or 3, It is characterized in that The pH of the first mobile phase is 5.0-6.5, and the pH of the second mobile phase is 9.0-11.
5.
5. The method according to claim 2 or 3, It is characterized in that The second mobile phase also includes water and / or sodium chloride. The pH of the first mobile phase is 5.0-6.5, and the pH of the second mobile phase is 9.0-11.
5.
6. The method according to claim 5, It is characterized in that In the first buffer solution, the concentrations of imidazole, 2-methylpiperazine and tris(hydroxymethyl)aminomethane are 2-12 mmol / L, 2-12 mmol / L and 2-12 mmol / L, respectively.
7. The method according to any one of claims 1 to 6, It is characterized in that The detection process is carried out in a high performance liquid chromatograph equipped with a cation exchange chromatography column, and the detection conditions are as follows: The column temperature is 10°C to 50°C, the flow rate is 0.2mL / min to 1.5mL / min, the injection volume is 5μL to 100μL, and the detector is an ultraviolet detector, a diode array detector or a fluorescence detector.
8. The method according to claim 1, It is characterized in that The sample is a bulk drug and / or a preparation comprising at least two antibodies and their acid-base charge heterogeneities.
9. The method according to claim 7, It is characterized in that Each of the antibodies is a monoclonal antibody, or at least one of the antibodies is a bispecific antibody.
10. The method according to claim 8, It is characterized in that When the sample includes a formulation, the formulation is a single co-prescribed protein formulation, or a mixture of at least two single co-prescribed protein formulations.
